Company intelligence / Profile preview

Yangli Group

Shenzhen, Guangdong, Chinaen.yangli.com ↗

Ownership: Private
Development stage: Other

Overview

Shenzhen Yangli Pharmaceutical Technology has several small molecule programs in early clinical development targeting cancer indications such as advanced solid tumors and ER-positive/HER2-negative breast cancer. Their lead assets include PARP1 inhibitors, ER degraders, and 17β-HSD5 inhibitors currently in Phase 1/2 or Phase 2 trials. The company holds patents on novel PARP1 inhibitor compounds for oncology and potentially other diseases like ischemia or neurodegeneration but no late-stage or commercialized products yet.

Therapeutic areas: Oncology
Modalities: Small molecule drugChemical drugs
Industry: Biotech

Beyond the preview

Go deeper on Yangli Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yangli Group.

Explore the full profile